Skip to Main Content
Economic evidence

In a recent randomized controlled trial by Kalowes et al, Mepilex® Border Sacrum was associated with an 88% reduction in risk of  of pressure ulcers. For an ICU department with 1,000 admissions, this pressure ulcer reduction could translate to significant cost savings.

The authors state:

"Cost savings for our health system have been significant ... Organizational estimates demonstrate that a savings of more than $1 million has been amortized in the past two years, after dressing purchase. This estimate is most likely conservative, given that the Society of Actuaries estimates the cost of treating a pressure ulcer ranges from $2,000 to $20,000 per ulcer, depending on severity. This cost savings estimate related to prevention is also consistent with other cost analysis studies of pressure ulcers."   

View our other economic studies
Economic studies